Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS
17 Jul 2026
bởiStephen Padilla
The investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib demonstrates its noninferiority to ocrelizumab in reducing the risk of disability progression in patients with primary progressive multiple sclerosis (PPMS) in the phase III FENtrepid study.
Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS
17 Jul 2026
Older age, overweight raise risk of symptomatic VTE in DFF patients
16 Jul 2026
bởiStephen Padilla
A Singapore study has observed a high prevalence of symptomatic venous thromboembolism (VTE) in patients who underwent distal femur fracture (DFF) surgery. Those with advanced age or who are overweight are more likely to develop symptomatic VTE.







